Insights

Why the Immutep (ASX:IMM) share price is charging higher today

Researchers are pursuing the silver bullet to defeat cancer.
The post Why the Immutep (ASX:IMM) share price is charging higher today appeared first on The Motley Fool Australia. –

Immutep Ltd (ASX: IMM) shares are lifting on Thursday morning following an clinical trial update from the company. At the time of writing, the Immutep share price is trading 2% higher at 51 cents.

Below we take a look at the ASX healthcare company’s latest news.

What update did Immutep report?

The Immutep share price is gaining after the biotechnology company reported the first patient had been dosed in its clinical cancer fighting trial, INSIGHT-003.

The investigator-initiated trial is taking place at the Institute of Clinical Cancer Research IKF in Germany.

The first patient dosed has metastatic non-small cell lung carcinoma. According to the release, they received “pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha” (efti).

The company explains that efti is a soluble LAG-3 protein, which is being explored in cancer and infectious disease treatment.

Commenting on the commencement, chief medical officer Frédéric Triebel said:

INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered. We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity. Dosing the first patient in this trial is a significant milestone and it sets the wheels in motion for reporting first data which are currently anticipated in 2022.

Immutep expects to recruit up to 20 patients with solid tumours for the trial. They’ll receive 30 mg subcutaneous doses of efti every 2 weeks atop standard of care chemotherapy and anti-PD-1 therapy.

Immutep share price snapshot

The Immutep share price has been a stellar performer over the past 12 months, up 165%. By comparison the All Ordinaries Index (ASX: XAO) has gained 27% over that same time.

Year to date, the Immutep share price has continued to beat the benchmark, up by around 21% so far this calendar year.

Immutep reached multi-year highs on 4 June, hitting 67 cents per share.

The post Why the Immutep (ASX:IMM) share price is charging higher today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Immutep right now?

Before you consider Immutep, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Immutep wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Capital keeps flowing into ASX Biotech shares in 2021

The 5 best performing ASX healthcare shares of FY21, did yours make the cut?

The Immutep (ASX:IMM) share price is up 6% today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!